Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, called Vykat XR, are exceeding Wall Street expectations. Vykat XR is the first approved treatment for the insatiable hunger associated with Prader-Willi syndrome and was approved in the US on March 26 earlier this year.

For the three months ending June 30, Soleno anticipates net revenue from Vykat XR sales to be between $31 and $33 million. Since its approval, the company has received ~646 “start forms” from 295 physicians, which shows strong initial demand. While the quarterly performance review is ongoing and estimates could change, Stifel analyst James Condulis noted that these preliminary numbers are well-above investor expectations.

A line of biopharmaceutical products on a laboratory shelf waiting to be tested.

Prader-Willi syndrome is a rare genetic condition that affects an estimated 10,000 to 20,000 people in the US, characterized by behavioral and cognitive symptoms, most notably an all-consuming hunger (hyperphagia). Before Vykat XR, the management of the disease typically involved supportive care and human growth hormone.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of rare diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.